×
About 5,660 results

ALLMedicine™ Aspergillosis Center

Research & Reviews  1,888 results

CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and ind...
https://doi.org/10.1016/j.clinimag.2022.07.003
Clinical Imaging; Hong W, White PL et. al.

Aug 1st, 2022 - Common CT abnormalities of pulmonary aspergillosis represent a cavity with air-meniscus sign, nodule, mass, and consolidation having an angio-invasive pattern. This study aims to conduct a systematic review and an individual patient-level image an...

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
https://clinicaltrials.gov/ct2/show/NCT04218851

Aug 1st, 2022 - This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
https://clinicaltrials.gov/ct2/show/NCT04707703

Jul 29th, 2022 - Adult patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 (COVID-19) infection without a diagnosis of invasive aspergillosis who are hospitalized in the ICU are eligible for inclusion in this study and will be randomized to the isav...

Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cys...
https://doi.org/10.1183/16000617.0011-2022
European Respiratory Review : an Official Journal of the ... Manti S, Giallongo A et. al.

Jul 28th, 2022 - Aspergillus fumigatus is a common saprophytic fungus causing allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). The recommended first-line treatment for ABPA is oral steroids, followed by antifungal therapy. Howe...

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
https://clinicaltrials.gov/ct2/show/NCT03816176

Jul 27th, 2022 - Treatment will begin on Day 1 and then participants will be followed for 60 days post-last dose for safety. Treatment will be administered until the participant has a successful outcome or for a maximum duration of 84 days (IA) or 180 days (IM), w...

see more →

Guidelines  7 results

Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727169
American Journal of Respiratory and Critical Care Medicine; Hage CA, Carmona EM et. al.

Aug 31st, 2019 - Background: Fungal infections are of increasing incidence and importance in immunocompromised and immunocompetent patients. Timely diagnosis relies on appropriate use of laboratory testing in susceptible patients.Methods: The relevant literature r...

ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates a...
https://doi.org/10.1016/j.cmi.2019.05.019
Clinical Microbiology and Infection : the Official Public... Warris A, Lehrnbecher T et. al.

Jun 4th, 2019 - Presenting symptoms, distributions and patterns of diseases and vulnerability to invasive aspergillosis (IA) are similar between children and adults. However, differences exist in the epidemiology and underlying conditions, the usefulness of newer...

Individualized Medication of Voriconazole: A Practice Guideline of the Division of Ther...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250289
Therapeutic Drug Monitoring; Chen K, Zhang X et. al.

Sep 8th, 2018 - Voriconazole (VRZ) is a second-generation triazole antifungal agent with broad-spectrum activity. It is available in both intravenous and oral formulations, and is primarily indicated for treating invasive aspergillosis. The most commonly used dos...

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-...
https://doi.org/10.1016/j.cmi.2018.01.002
Clinical Microbiology and Infection : the Official Public... Ullmann AJ, Aguado JM et. al.

Mar 17th, 2018 - The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numero...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

see more →

Drugs  99 results see all →

Clinicaltrials.gov  168 results

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
https://clinicaltrials.gov/ct2/show/NCT04218851

Aug 1st, 2022 - This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
https://clinicaltrials.gov/ct2/show/NCT04707703

Jul 29th, 2022 - Adult patients with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 (COVID-19) infection without a diagnosis of invasive aspergillosis who are hospitalized in the ICU are eligible for inclusion in this study and will be randomized to the isav...

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
https://clinicaltrials.gov/ct2/show/NCT03816176

Jul 27th, 2022 - Treatment will begin on Day 1 and then participants will be followed for 60 days post-last dose for safety. Treatment will be administered until the participant has a successful outcome or for a maximum duration of 84 days (IA) or 180 days (IM), w...

Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
https://clinicaltrials.gov/ct2/show/NCT03672292

Jul 22nd, 2022 - This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety, tolerability, efficacy and PK of the coadministration of SCY-078 plus voriconazole compared to those of voriconazole in male and female subjects 18 years of age...

A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
https://clinicaltrials.gov/ct2/show/NCT04442269

Jul 20th, 2022 - The primary objective of the study is to evaluate the efficacy of dupilumab on the annualized rate of exacerbations in participants with Allergic Bronchopulmonary Aspergillosis (ABPA). The secondary objectives of the study are: To evaluate the eff...

see more →

News  96 results

Longer Course of Antifungal Therapy Protects Against Chronic Pulmonary Aspergillosis Relapse
https://www.medscape.com/viewarticle/972520

Apr 22nd, 2022 - NEW YORK (Reuters Health) - A 12-month course of itraconazole was superior to a six-month course at reducing relapses of chronic pulmonary aspergillosis in a randomized controlled trial conducted in India. "Preventing relapses and thereby further ...

Several Risk Factors Tied to Fatal Post-Liver Transplant Infections
https://www.medpagetoday.com/gastroenterology/livertransplantation/93965

Aug 9th, 2021 - Fewer than half of liver transplant patients who developed invasive fungal infections (IFI) died after surgery, with several key factors contributing to mortality risk, researchers found in a small retrospective study. Out of 33 patients who devel...

GM-EIA and BDG assays ineffective for IFD diagnosis in AML patients receiving antifungal prophylaxis
https://www.mdedge.com/hematology-oncology/article/243646/aml/gm-eia-and-bdg-assays-ineffective-ifd-diagnosis-aml-patients

Jul 30th, 2021 - Key clinical point: Twice-weekly surveillance with galactomannan enzyme immunoassay (GM-EIA) and b-D-glucan (BDG) assay was ineffective at detecting invasive fungal diseases (IFDs) in children, adolescents, and young adults with acute myeloid leuk.

Five Things You Need to Know About Bronchiectasis
https://www.medscape.com/viewarticle/955069

Jul 22nd, 2021 - Bronchiectasis is a chronic condition characterised by symptoms of persistent or recurrent bronchial sepsis caused by irreversible damage to and dilation of the bronchi.[1] The key principles of the diagnosis and management of bronchiectasis were ...

Posaconazole prophylaxis reduces breakthrough fungal infections in AML patients receiving induction chemotherapy
https://www.mdedge.com/hematology-oncology/article/242091/aml/posaconazole-prophylaxis-reduces-breakthrough-fungal

Jun 24th, 2021 - Key clinical point: In patients with acute myeloid leukemia (AML) receiving induction chemotherapy, the incidence of breakthrough invasive fungal diseases (IFDs) and consequent use of therapeutic antifungal agents were significantly lower in patie.

see more →

Patient Education  6 results see all →